1832 Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-1,406,500
Closed -$152M 1012
2021
Q4
$152M Buy
1,406,500
+1,318,180
+1,493% +$144M 0.27% 96
2021
Q3
$9.76M Buy
+88,320
New +$9.17M 0.02% 336

Other funds holding HZNP

1832 Asset Management's HZNP Position: Q1 2022 in Review

1832 Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2022, closing a stake of 1,406,500 shares — an estimated $152M sold.

1832 Asset Management first reported a position in HZNP in Q3 2021 and held it in 2 quarters. The position peaked at $152M in Q4 2021. 620 funds tracked by Wall St. Rank hold HZNP as of Q1 2022.

  • 1832 Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2022 after selling out during the quarter.
  • 1832 Asset Management sold 1,406,500 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2022, an estimated $152M.
  • 1832 Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 2 quarters.
  • 1832 Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $152M in Q4 2021.
  • 620 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2022.

Based on 1832 Asset Management's 13F filing for Q1 2022, filed 16 May 2022.